Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 10/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097695 | 0.86 | PKM (0.55) | KMT2APKMMAPTNPC1MEN1 | |
| SCHEMBL7100941 | 0.80 | PKM (0.54) | KMT2APKMMAPTNPC1MEN1 | |
| SCHEMBL7412959 | 0.79 | PKM (0.53) | KMT2APKMMAPTNPC1MEN1 | |
| SCHEMBL7103983 | 0.77 | PKM (0.52) | KMT2APKMMAPTNPC1MEN1 | |
| SCHEMBL7101468 | 0.77 | PKM (0.55) | KMT2APKMMAPTNPC1MEN1 | |
| SCHEMBL18184326 | 0.76 | KMT2A (0.65) | KMT2APKMMAPTNPC1MEN1 | |
| SCHEMBL7097462 | 0.75 | PKM (0.49) | KMT2APKMMAPTNPC1MEN1 | |
| SCHEMBL7097045 | 0.75 | MAPT (0.52) | KMT2AMAPTNPC1MEN1MAPK1 | |
| SCHEMBL7519497 | 0.75 | KMT2A (1.00) | KMT2APKMMAPTNPC1MEN1 | |
| SCHEMBL709343 | 0.74 | KMT2A (0.65) | KMT2APKMMAPTNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6593355-B2 | 2-phenylaminomethyl benzimidazole derivatives | BOEHRINGER INGELEHIM PHARMA KG (DE) | 2003-07-15 | — | — | US | disclosed |
| US-20030004356-A1 | Benzimidazoles with antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-02 | — | — | US | disclosed |
| EP-1095025-B1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1244636-A1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND THE USE THEREOF AS ANTITHROMBOTIC | Boehringer Ingelheim Pharma KG (DE) | 2002-10-02 | — | — | EP | disclosed |
| US-6451832-B2 | E.G., 2-(AMINDINOPHENYLAMINOMETHYL)-1-METHYL-5-(1-(ETHOXY-CARBONYL-METHYLAMINO)-1 -(2,5-DIHYDROPYRROLOCARBONYL)-ETHYL)BENZIMIDAZOLE; ANTICOAGULANTS AND ANTITHROMBOLYTIC AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-09-17 | — | — | US | disclosed |
| WO-2001047896-A1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND THE USE THEREOF AS ANTITHROMBOTIC | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-07-05 | — | — | WO | disclosed |
| US-20010006977-A1 | Benzimidazoles with antithrombotic activity | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-07-05 | — | — | US | disclosed |
| US-6248770-B1 | CARDIOVASCULAR DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-06-19 | — | — | US | disclosed |
| US-6200976-B1 | FOR TREATING THROMBOSIS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-13 | — | — | US | disclosed |
| EP-1071669-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999054313-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004356-A1 | Benzimidazoles with antithrombotic activity | SERPINC1, SERPINB1, PF4 | KMT2A 2154/4885PKM 958/4885MAPT 4862/4885 |
| US-20010006977-A1 | Benzimidazoles with antithrombotic activity | SERPINC1, SERPINB1, PF4 | KMT2A 2154/4885PKM 958/4885MAPT 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.